ArticleEuropean journal of endocrinology2017
Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total
Article in European journal of endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Pooled it
- Article
- Article
- [Cancers · 2025Article
- Progress report on multiple endocrine neoplasia type 1.Familial cancer · 2025Review
- New Developments in VHL-Associated Neuroendocrine Neoplasms.Current oncology reports · 2025Review
- AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT.European journal of hybrid imaging · 2023Article
- Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.Cancers · 2023Review
- A physiologically based pharmacokinetic model for [EJNMMI research · 2023Article
- Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET.Journal of neuroendocrinology · 2022Article
- Is There a Role for Biomarkers in Surveillance of Pancreatic Neuroendocrine Neoplasms in Von Hippel-Lindau Disease?Journal of the Endocrine Society · 2022Review
- Neuron-Specific Enolase and Hemoglobin as Risk Factors of Intraocular Metastasis in Patients with Renal Cell Carcinoma.Disease markers · 2022Article
- Targeting vulnerable atherosclerotic plaque via PET-tracers aiming at cell-surface overexpression of somatostatin receptors.Biomedical reports · 2020Article
- PET/CT and PET/MRI in ophthalmic oncology (Review).International journal of oncology · 2020Review
- Von Hippel-Lindau Disease: Current Challenges and Future Prospects.OncoTargets and therapy · 2020Review
- Prognostic value of somatostatin receptor expressing tumor volume calculated fromEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary.Pancreas · 2019Review
- Management of Gastrointestinal Neuroendocrine Tumors.Clinical medicine insights. Endocrinology and diabetes · 2019Review
- Role of biomarker tests for diagnosis of neuroendocrine tumours.Nature reviews. Endocrinology · 2018Review
- Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base.Journal of the Endocrine Society · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 4 countries.
Funding
Abstract
objectiveTo determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by
designA retrospective analysis of a prospective database of patients with NETs.
methodsFasting plasma chromogranin A (CgA), neuron-specific enolase (NSE), gastrin, glucagon, vasoactive intestinal peptide (VIP) and pancreatic polypeptide (PP), and 24-h urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were measured. Correlation between biomarkers and total
resultsThe analysis included 232 patients. In patients with pancreatic NETs (
conclusionsOur data supports the use of specific NET biomarkers based on the site of the primary NET and the presence of hereditary syndrome-associated NET. High urinary 5-HIAA levels indicate the presence of metastatic disease in patients with SINET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.